...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients
【24h】

Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients

机译：英夫利昔单抗诱导类风湿关节炎患者严重牙周生物标志物的解离反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Rheumatoid arthritis and periodontal disease are associated together, but the effect of therapy provided for one disease to the second one remained under-investigated. This study investigated effect of infliximab therapy used to treat rheumatoid arthritis (RA) on various biomarkers of periodontal disease (PD) severity including serologies of Porphyromonas gingivalis and Prevotella intermedia and matrix metalloproteinase 3. Methods: Seventy nine RA patients were enrolled at the time to start infliximab therapy and the 28 joint disease activity score (DAS28), anti-cyclic citrullinated petides 2nd generation (anti-CCP2), anti- P. gingivalis antibody, and Matrix metalloproteinase 3 (MMP-3) were monitored before and at 6 months of infliximab therapy. Joint damage and severe periodontal disease were assessed at baseline. Anti-CCP2, anti- P. gingivalis antibody, and MMP-3 were determined by enzyme-linked immunosorbent assay (ELISA). Results: At baseline, anti-CCP2 titers were associated with anti- P. gingivalis lipopolysaccharide (LPS)-specific antibodies titers ( p 0.05). Anti- P. gingivalis antibodies were not significantly correlated with clinical, biological, or destruction parameters of RA disease. At 6 months of infliximab therapy, MMP-3 level decreased (from 119 ± 103 ng/mL to 62.44 ± 52 ng/mL; p 0.0001), whereas P. gingivalis antibody levels remained at the same level. DAS28 and inflammation markers C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) also decreased significantly during infliximab therapy ( p 0.05) as anti-CCP2 levels ( p 0.001). Only high MMP-3 level at baseline was associated with infliximab efficacy ( p 0.01). Conclusion: MMP-3 level can be a useful marker of the efficacy of infliximab in RA patients. The treatment did not affect anti- P. gingivalis antibodies.
机译：目的：类风湿关节炎和牙周疾病相关联，但对一种疾病至第二种疾病的治疗效果仍未得到充分研究。这项研究调查了用于治疗类风湿性关节炎（RA）的英夫利昔单抗治疗对牙周疾病（PD）严重程度的各种生物标志物的影响，包括牙龈卟啉单胞菌，中间型普氏杆菌和基质金属蛋白酶3的血清学方法。开始英夫利昔单抗治疗，并在6个月之前和6个月时监测了28个关节疾病活动评分（DAS28），第二代抗环瓜氨酸肽（anti-CCP2），抗牙龈卟啉单胞菌抗体和基质金属蛋白酶3（MMP-3）英夫利昔单抗治疗。在基线时评估关节损伤和严重的牙周疾病。抗CCP2，抗齿龈假单胞菌抗体和MMP-3通过酶联免疫吸附测定（ELISA）确定。结果：在基线时，抗CCP2滴度与抗齿龈假单胞菌脂多糖（LPS）特异性抗体滴度相关（p <0.05）。抗齿龈假单胞菌抗体与RA疾病的临床，生物学或破坏参数无显着相关性。在英夫利昔单抗治疗的6个月时，MMP-3水平降低（从119±103 ng / mL降至62.44±52 ng / mL; p <0.0001），而牙龈卟啉单胞菌抗体水平保持相同水平。在英夫利昔单抗治疗期间，DAS28和炎症标志物C反应蛋白（CRP）和红细胞沉降率（ESR）也显着降低（p <0.05），作为抗CCP2水平（p <0.001）。基线时只有较高的MMP-3水平与英夫利昔单抗的疗效相关（p <0.01）。结论：MMP-3水平可能是英夫利昔单抗在RA患者中的有效指标。该治疗不影响抗牙龈卟啉单胞菌抗体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号